Pfizer, Bristol-Myers get EU approval for blood clot preventer
Nov 20 (Reuters) - European health regulators on Tuesday approved an eagerly anticipated blood thinner developed by Bristol-Myers Squibb Co and Pfizer Inc for the prevention of strokes and blood clots in patients who have an irregular heartbeat known as atrial fibrillation, the companies said.
The drug Eliquis, also known as apixaban, is widely considered one of the most important new products for the two U.S. drugmakers, with multibillion-dollar annual sales potential.
The U.S. Food and Drug Administration is expected to make its decision on the drug for use in the world's biggest market by March 17, after delaying a decision in June so that the agency could review additional information from clinical trials of the medicine.
- Malaysian plane presumed crashed; questions over false IDs |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Malaysian plane crashed off Vietnam coast: state media